Inhibitors of a signaling pathway that is critical to synovial sarcoma tumorigenesis may be useful treatments for this aggressive cancer.

John F. Brock III, chairman and CEO of Coca-Cola Enterprises, his wife, Mary, and their three children have established an endowment to support an oncology fellowship at Vanderbilt-Ingram Cancer Center. The Brock Family Fellowship will provide financial assistance long into the future for young physicians, postdoctoral students and medical investigators who are furthering their training in cancer research.

Vanderbilt researchers have used bioinformatics analysis of gene expression data to describe molecular “circuits” that drive ovarian cancer.

David Cortez, Ph.D., and his Vanderbilt colleagues report new findings that shed light on fundamental processes involved in DNA replication and have implications for cancer therapies that target these processes.

A group of Vanderbilt researchers has used laser technology and a custom-built multiphoton microscope to distinguish breast cancer subtypes and determine if specific therapies are working against the cancer cells in as little as two days.

Understanding the regulation of mutant EGF receptors commonly found in lung cancers could lead to new targeted therapies.

Molecular characterization of pre-cancerous changes in cells lining the stomach could point to lesions with a greater risk of progression to cancer.